Sherbrooke Park Advisers LLC Krystal Biotech, Inc. Transaction History
Sherbrooke Park Advisers LLC
- $313 Billion
- Q4 2024
A detailed history of Sherbrooke Park Advisers LLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Sherbrooke Park Advisers LLC holds 2,353 shares of KRYS stock, worth $360,573. This represents 0.12% of its overall portfolio holdings.
Number of Shares
2,353
Previous 2,379
1.09%
Holding current value
$360,573
Previous $433 Million
14.88%
% of portfolio
0.12%
Previous 0.1%
Shares
4 transactions
Others Institutions Holding KRYS
# of Institutions
297Shares Held
24.3MCall Options Held
388KPut Options Held
233K-
Black Rock Inc. New York, NY3.95MShares$605 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.88MShares$441 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.63MShares$403 Million6.0% of portfolio
-
State Street Corp Boston, MA1.28MShares$196 Million0.01% of portfolio
-
Capital World Investors Los Angeles, CA879KShares$135 Million0.02% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $3.93B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...